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Epilepsy with auditory features
A heterogeneous clinico-molecular disease
ABSTRACT
Objective: To identify novel genes implicated in epilepsy with auditory features (EAF) in phenotyp-
ically heterogeneous families with unknown molecular basis.
Methods: We identified 15 probands with EAF in whom an LGI1 mutation had been excluded. We
performed electroclinical phenotyping on all probands and available affected relatives. We used
whole-exome sequencing (WES) in 20 individuals with EAF (including all the probands and 5 rela-
tives) to identify single nucleotide variants, small insertions/deletions, and copy number variants.
Results:WES revealed likely pathogenic variants in genes that had not been previously associated
with EAF: a CNTNAP2 intragenic deletion, 2 truncating mutations of DEPDC5, and a missense
SCN1A change.
Conclusions: EAF is a clinically and molecularly heterogeneous disease. The association of EAF
with CNTNAP2, DEPDC5, and SCN1A mutations widens the phenotypic spectrum related to
these genes. CNTNAP2 encodes CASPR2, a member of the voltage-gated potassium channel
complex in which LGI1 plays a role. The finding of a CNTNAP2 deletion emphasizes the impor-
tance of this complex in EAF and shows biological convergence. Neurol Genet 2015;1:e5; doi:
10.1212/NXG.0000000000000005
GLOSSARY
ADEAF 5 autosomal dominant EAF; CADD 5 Combined Annotation-Dependent Depletion; CNV 5 copy number variant;
EAF 5 epilepsy with auditory features; FS 5 febrile seizure; GEFS1 5 generalized epilepsy with febrile seizures plus;
InDels 5 insertions and deletions; OMIM 5 Online Mendelian Inheritance in Man; RVIS 5 Residual Variation Intolerance
Score; SNV 5 single nucleotide variant; VGKC 5 voltage-gated potassium channel; WES 5 whole-exome sequencing.
Epilepsy with auditory features (EAF) is an uncommon presentation of focal epilepsy character-
ized by focal seizures with auditory auras and symptoms suggesting lateral temporal onset.1 EAF
is the hallmark of autosomal dominant EAF (ADEAF),1–3 a familial epilepsy syndrome due to
mutations of the leucine-rich, glioma-inactivated 1 (LGI1) gene (Online Mendelian Inheritance
in Man [OMIM] *604619)4 in 50% of families.5 In ADEAF, affected members typically have
EAF, although to make the diagnosis only 2 family members need to have EAF, irrespective of
their degree of relatedness and the total number of individuals with epilepsy in the family.5,6
EAF also occurs in sporadic cases or in pedigrees with no LGI1 mutation. In these pedi-
grees, EAF is indistinguishable from LGI1-positive ADEAF. However, the pattern of inher-
itance may be unclear, there may be phenotypic heterogeneity and EAF may occur in only
a minority of cases. Such families do not usually fulfill the criteria for any specific familial
epilepsy syndrome.
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The small size, clinical heterogeneity, and
incomplete penetrance displayed by such fam-
ilies with EAF may have hampered gene map-
ping through traditional approaches, such as
linkage analysis. No mutation in genes other
than LGI1 has been identified so far in
EAF.7–10 The advent of next-generation
sequencing has made the identification of
causal variants possible even in small families.
In this study, we describe a comprehensive
whole-exome sequencing (WES) approach
that enabled us to identify likely pathogenic
variants in EAF probands and their affected
relatives, demonstrating genetic heterogeneity
underlying this epilepsy phenotype.
METHODS Families. From 2001 to 2014, we recruited con-
secutive probands with EAF and family history of epilepsy (at
least 1 relative within 3 degrees of kinship affected with EAF or
other epilepsy).
All affected family members underwent phenotyping, includ-
ing medical and seizure history, neurologic examination, EEG
recordings, and brain MRI. Previous medical records were
obtained.
Standard protocol approvals, registrations, and patient
consents. We received approval from institutional ethical stand-
ards committee on human experimentation, and written
informed consent was obtained from all patients participating
in the study or their parents in the case of minors.
Molecular genetic analysis. WES was performed on 20 indi-
viduals: 15 probands and 5 relatives with EAF. DNA was
extracted from peripheral blood using the QIAamp DNA Blood
Mini Kit (Qiagen, Venlo, the Netherlands) following the manufac-
turer’s protocol. Whole-exome DNA was captured using the
NimbleGenSeqCap EZ Exome v3 array (Nimblegen Inc.,
Madison, WI) and sequenced as 91-bp paired-end reads on the
Illumina HiSeq2000 platform (Illumina Inc., Santa Clara, CA) at
Beijing Genomic Institute (Shenzhen, China). Reads were processed
following a general analysis pipeline described elsewhere.11
Single nucleotide variants (SNVs) and small insertions and
deletions (InDels) were called with the Genome Analysis
ToolKit,12 and copy number variants (CNVs) were called from
WES data using EXCAVATOR.13 Among SNVs and InDels,
nonsynonymous SNVs, splice-site substitutions, and coding
small insertions/deletions with a population allele frequency
,1& in public databases (1000 Genomes, http://www.
1000genomes.org; Exome Variant Server, http://evs.gs.wash-
ington.edu/EVS/; ExAC, http://exac.broadinstitute.org) and
absent from approximately 200 patients without epilepsy in
our internal exome database were considered further.
The priority assigned to variants was higher in those with a
lower Residual Variation Intolerance Score (RVIS) percentile
(indicating greater intolerance to functional variation)14 and
in those predicted to have a likely functional effect by Com-
bined Annotation-Dependent Depletion (CADD) score15
(higher CADD scores indicate that the variant is more likely
to be functionally relevant), or predicted to alter splicing or to
be protein-truncating (frame-shift InDels or nonsense SNVs).
Among CNVs, a higher priority was assigned to events that
were not observed to occur in regions known to be involved
in segmental duplications or were rare (allele frequency ,1&)
in the Database of Genomic Variants (http://dgv.tcag.ca/dgv/
app/home) by manual inspection. When WES of 2 affected
members of the family (table 1) had been performed, only the
variants shared by the 2 were retained.
Validation and segregation analysis of candidate variants and
CNVs were performed using Sanger sequencing and quantitative
PCR analyses, respectively, following standard protocols.
RESULTS We included 12 consecutive probands of
Italian ancestry attending the Epilepsy Center of
our Institute in Bologna. Three additional cases were
referred by 2 other epilepsy centers in Italy. A muta-
tion or CNV of LGI116 was excluded in all 15 pro-
bands with EAF. Pedigree analysis revealed a total of
34 affected relatives: 6 with EAF (in the 5 families A,
D, G, H, and I in table 1) and 28 with other epilepsy
(table 1). Two families have been previously
reported,6,17 while the remaining 13 pedigrees are
described here for the first time.
Molecular genetic findings in 344 “epilepsy genes.” To
analyze WES data, we initially focused on a set of
344 genes (table e-1 at Neurology.org/ng) implicated
in monogenic disorders including epilepsy as a
phenotypic feature based on previously published
work18 and the OMIM database (www.omim.org).
We identified 7 candidate variants of 5 genes, each
in one of 7 families. These variants were validated in
every individual who underwent exome testing.
We then tested segregation in all the available
family members, both unaffected and affected by
EAF or other epilepsies, who had no WES
performed. After testing segregation, 6 variants
remained: 1 CNV in CNTNAP2 (contactin-
associated protein-like 2; OMIM *604569), 1 SNV
and 1 InDel in DEPDC5 (DEP domain-containing
protein 5; OMIM *614191), 1 SNV in SCN1A
(sodium channel, voltage-gated, type 1, alpha
subunit; OMIM *182389), 1 SNV in CACNA1H
(calcium channel, voltage-dependent, T type,
alpha-1H subunit; OMIM *607904), and 1 SNV
in RELN (REELIN, OMIM *600514).
Likely pathogenic variants. CNTNAP2. An intragenic
deletion of CNTNAP2 (p.Gln33Argfs*7) was identi-
fied in both the affected members of family A
(figure 1). The proband (A:IV:1), aged 47 years, pre-
sented at 9 years with episodes characterized by con-
fusion, distortion of voices, and inability to speak,
occasionally followed by a bilateral tonic-clonic sei-
zure. From 37 years of age, she had an aura of the
noise of a train followed by an aphasic phase and some-
times twitching of her mouth and left arm, drooling,
and head deviation to the right. Interictal EEG showed
left temporal theta activity, and brain MRI was unre-
markable. Her father (A:III:1) experienced seizures
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with auditory phenomena and rare bilateral tonic-
clonic seizures from 15 to 18 years. The CNV of
CNTNAP2 identified spans about 270 kb across exons
2-3 and is predicted to produce an out-of-frame tran-
script p.Gln33Argfs*7 (NM_014141:c.98_402del)
and to result in loss of function.
DEPDC5. Two different truncating mutations of
DEPDC5 were found in 2 probands. Both DEPDC5
variants were predicted to be loss-of-function alleles.
A single base out-of-frame deletion
p.Leu1371Argfs*14 (NM_001136029:c.4112delT)
was detected in 3 affected members of family B (figure
1). The proband (B:III:1) with EAF had onset at 12
years of episodes comprising “a sensation of a whistle
in the right ear,” sometimes associated with a rising
epigastric sensation and followed by impairment of
awareness and gestural automatisms. Interictal EEG
showed bitemporal theta activity. The other 2
affected members have other types of focal epilepsy.
Her mother (B:II:1) developed focal seizures at 9
years characterized by a rising epigastric sensation
and autonomic phenomena followed by impaired
awareness and head deviation. Her maternal aunt
(B:II:2) experienced focal seizures from 9 years that
began with a nonspecific aura and sometimes evolved
to a bilateral tonic-clonic seizure. Her EEG showed
right temporal sharp wave complexes.
In family C (figure 1), we identified a stop-gain
substitution p.Tyr306*(NM_001136029:c.C918G).
The proband (C:IV:1) had a single febrile seizure
(FS) at 6 months of age and then had rare right
tonic seizures, occasionally followed by a bilateral
tonic-clonic seizure, predominantly during sleep
until 2 years of age. Since childhood, she has also
had seizures preceded by auditory phenomena and/or
déjà vécu, sometimes followed by impaired conscious-
ness. By 29 years, seizures occurred weekly, despite
trials of several antiepileptic drugs. Interictal EEG
showed bitemporal theta activity. Her mother (C:
III:2) had FSs at 2 years and focal seizures beginning
with visual phenomena, déjà vu, and an epigastric aura
between 12 and 35 years. Brain MRI was normal in all
patients from both families.
SCN1A. In family D (figure 1), a missense
change p.Met956Thr (NM_001165963:c.T2867C)
of SCN1A was identified in the proband (D:III:1)
and her daughter (D:IV:1) with EAF. The family
comprised 10 affected members (3 male, 7 female;
mean age at onset: 4.5 years, range: 2–12). Seven
had epilepsy (D:III:1, D:III:7, D:III:8, D:IV:1, D:
IV:6, D:IV:7, and D:IV:8), while 3 had FSs alone
(D:III:6, D:III:11, and D:IV:4). In addition to indi-
viduals D:III:1 and D:IV:1 with EAF, 1 patient had
focal epilepsy (D:III:8), 3 had generalized seizures in
Table 1 Clinical features of the affected members belonging to the 15 pedigrees
Family
No.
affected M/F Kinship
Mean
age, y
Mean age at
onset, y (range)
Epilepsy, no. of individuals No./no. individuals tested
EAF
Other
focal Unclassifieda GS EE FS SG
EEG
epileptiform
Brain MRI
abnormalities
Ab 3 2/1 I, III 63 12 (9–15) 2 — 1 — — — 2 0/1 0/1
B 3 0/3 I, II 25.3 10 (9–12) 1 2 (T; ns) — — — — 1 1/3 0/3
C 3 0/3 I, $IV 45 6.2 (6 mo–12) 1 1 (T) 1 — — 2 1 1/1 0/2
Db 10 3/7 I, $IV 37.8 4.5 (2–12) 2 1 (T-P-O) — 3 1 6 3 4/6 0/4
E 2 0/2 I 50 25 (14–36) 1 1 — — — 1 0/1 0/1
F 2 2/0 II 52 16 (on 1) 1 — 1 — — — 1 0/1 0/1
Gb 4 3/1 I, $IV 46.25 21.25 (15–27) 3 — 1 — — 1 2 2/4 0/2
Hb 3 2/3 I 61 31.6 (22–46) 2 — 1 — — — 2 0/3 0/3
Ib 2 0/2 I 46.5 12 (6–18) 2 — — — — — 2 1/1 1/1
J 2 0/2 I 49 17 (13–21) 1 1 (T) — — — — 2 1/2 0/2
K 2 0/2 III 50.5 37 (14–60) 1 — 1 — — — 1 2/2 0/2
L 3 2/1 I, III 60.5 10 (6–14) 1 — 2 — — 1 1 1/1 1/1
M 4 0/4 I, III, $IV 44.3 12 (10–16) 1 — 3 — — — 1 1/1 0/1
N 2 1/1 II 36.5 10 (7–13) 1 — 1 — — — 1 0/1 0/1
O 4 0/4 I, III, $IV 35.3 19 (5–33) 1 2 (F/T; T) 1 (na) — — — 2 1/3 0/2
Abbreviations: EAF 5 epilepsy with auditory features; EE 5 epileptic encephalopathy; F/T 5 frontal or temporal; FS 5 febrile seizure; GS 5 generalized
seizures (including absence seizures, primarily generalized tonic-clonic seizures); na 5 not available; ns 5 not specific (aura: anticipation); SG 5 focal
seizures with secondary generalization; T 5 temporal; T-P-O 5 temporo-parieto-occipital.
a Unclassified epilepsy includes tonic-clonic seizures, unknown whether primary or secondary generalized.
b Families with at least 2 members with EAF.
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childhood (D:III:7, D:IV:6, and D:IV:8), and 1 had
infantile epileptic encephalopathy (D:IV:7). Three of
the family members with epilepsy had a history of
prolonged FSs (D:III:8, D:IV:1, and D:IV:8). The
SCN1A change segregated with affected status in this
large pedigree. There was incomplete penetrance
(61.5%) since 2 unaffected obligate carriers (D:II:4
and D:III:4) and 3 healthy individuals (D:III:3,
Figure 1 Segregation and localization of the identified variants
Pedigrees of the mutated families with mutations and schematic representation of the genes and the identified variants are presented. Phenotype labels:
EAF 5 epilepsy with auditory features; GTCS 5 generalized tonic-clonic seizures; GS 5 generalized seizures; FS 5 febrile seizures; unclassified: it is
undetermined whether the seizure type is focal or generalized. Gene diagrams and variants: blue lines represent the genomic regions spanned by the gene,
while the blue bars represent the exons. Colored blocks surrounding gene regions correspond to the protein domains encoded by the embedded exons. DEP
5 Dishevelled, Egl-10 and Pleckstrin domain; D1-4 5 domains 1–4; F5/8 5 discoidin domain; LGL 5 laminin G-like domain; EL 5 EGF-like domain; FCT 5
fibrinogen C-terminal domain; TM 5 transmembrane domain. The probands’ Sanger sequencing electropherogram surrounding the variant site is reported.
The histogram plot represents the result of the real-time PCR. Log2ratios of DDCt from patient A:III:1, patient A:IV:1, and a normal individual each against a
control sample are plotted. The control sample is one that was negative forCNTNAP2 rearrangements by array comparative genomic hybridization analyses.
Four probes were tested. Probe 1 and probe 2 are located in intron 1, while probe 3 and probe 4 are located in intron 3.
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D:III:5, and D:III:9) were heterozygous for the muta-
tion. The same mutation has been recently reported
in a family with intractable childhood epilepsy with
generalized tonic-clonic seizures where it was
described as a loss-of-function, fully penetrant allele
that led to incorrect folding of the alpha 1 subunit of
the voltage-gated sodium channel type 1 (Nav1.1)
encoded by SCN1A.19
Variants of unclear significance. CACNA1H. A missense
change p.Arg1669Gln (NM_001005407:c.G5006A)
of CACNA1H was identified in the 38-year-old pro-
band of family E (table 1).
The CACNA1H SNV identified was inherited by
her mother (E:I:1), who experienced sleep-related bilat-
eral tonic-clonic seizures at 36 years of age. Rare amino
acid substitutions altering function of the channel en-
coded by CACNA1H have been reported in families
with predominantly generalized epilepsies, as well as
temporal lobe epilepsy.20 The present change was poten-
tially deleterious (table e-2). Functional assessment of
the pathogenic potential was not performed as part of
this study but is needed to confirm a causal role.
RELN. A missense change p.Asp3323Glu
(NM_005045:c.T9969G) of RELN was identified
in the 52-year-old proband of family F (table 1). Seg-
regation of the variant could not be tested since no
relative was available for this study. The father’s
grandfather, who was the only other affected member
of the family (table 1), was already deceased at the
time of enrollment. RELN encodes reelin, which is
essential for cerebral cortex development and synaptic
function in the adult brain.21 Homozygous recessive
loss-of-function RELN alleles have been shown to
cause lissencephaly22 (OMIM #257320), while het-
erozygous variants have been purported to play a role
in neuropsychiatric disorders.21 Reelin is a huge pro-
tein (3460 aa, Uniprot ID P78509). Although RELN
is highly intolerant to functional variation and the
present variant is potentially deleterious (table e-2),
many rare missense variants accumulate in RELN
(ExAC database). Due to the lack of segregation test-
ing and uncertainty of its functional effect, we cannot
assess a causal role of this heterozygous variant.
Possible novel candidate genes. We further analyzed
WES data looking at variants in genes beyond the ini-
tial set. In order to identify possible candidates for
EAF, we examined variants within genes shared by
at least 2 unrelated probands. We validated and tested
the segregation of variants in 4 genes, selected based
on the lowest RVIS scores and the highest pathogenic
potential. After testing the segregation, only the echi-
noderm microtubule associated protein-like 6 gene
(EML6) remained as a possible candidate gene.
EML6 showed a novel p.Ala186fs frameshift event
(c.558delA) in family M and a rare p.Thr918Ala
missense variant (c.A2752G) in family F (table e-2).
The function of EML6 is largely unknown, and apart
from its reported expression in cerebral temporal
cortex (http://www.braineac.org/), no data support
its possible dysfunction being implicated in epilepsy.
Moreover, a major role in disease for any of the variants
in EML6 and RELN, which have both been found in
family F, is difficult to ascertain. Study of larger cohorts
will be needed to assess whether this gene can
contribute to EAF.
DISCUSSION In this study, we describe defects in
novel genes contributing to the genetic architecture
of EAF. We identified likely pathogenic genetic
variants in 4 of 15 unrelated EAF probands: an intra-
genic deletion of CNTNAP2, 2 truncating mutations
of DEPDC5, and 1 missense mutation in SCN1A. All
genes have been previously associated with other forms
of focal epilepsy but not EAF.23–26 Several factors sup-
port the pathogenicity of the identified mutations,
including their rarity, their predicted deleterious
nature, their segregation with affected status within
kindreds, and the recognized role of mutations of these
genes in the etiology of the associated epilepsies. In
these families, EAF is a phenotype that occurs in few
(often the minority) of the affected members. Such
phenotypically heterogeneous families are generally of
small size and have usually been considered poorly
informative for genetic studies, as recurrence of the
disease tends to be low, expressivity of the phenotype
widely variable, and penetrance reduced. These fami-
lies likely reflect the more common scenario in clinical
practice compared with the rare familial epilepsy syn-
drome of ADEAF. LGI1mutations are associated with
ADEAF in about half of the large multigenerational
families displaying autosomal dominant inheritance of
EAF. However, LGI1 mutations have been rarely de-
tected in pedigrees with EAF and a less clear-cut
pattern of inheritance or phenotypic heterogeneity.5
The discovery of DEPDC5 mutations in 2 of 15
probands is in line with the frequency of DEPDC5
mutations observed in other focal epilepsies (around
10%).23,27 The 2 identified DEPDC5 mutations
(c.C918G and c.4112delT) are loss-of-function
events, both predicted to generate a prematurely trun-
cated product. These mutated transcripts likely
undergo nonsense-mediated decay leading to hap-
loinsufficiency, which is the main mechanism
believed to underlie pathogenesis.23,28 These results
enlarge the DEPDC5-related phenotypic spectrum
to include EAF with lateral temporal lobe semiology,
further strengthening the emerging association of de-
fects in this gene with a broad range of focal epilep-
sies. It could be anticipated that different epilepsy
phenotypes, including EAF, will be associated with
DEPDC5 mutations in other small families.
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Similarly, the discovery of an SCN1A c.T2867C
change in family D widens the already large compen-
dium of epilepsy phenotypes associated with SCN1A
mutations. In this interesting pedigree, the EAF phe-
notype is limited to the proband and her daughter,
but expanding the clinical and genetic study of this
family allowed us to define the diagnosis of the famil-
ial epilepsy syndrome of generalized epilepsy with
febrile seizures plus (GEFS1). SCN1A has been
implicated in different epilepsy syndromes ranging
from GEFS129 to Dravet syndrome (OMIM
#607208)30 and occasionally includes focal seiz-
ures.24,25 Lateral temporal semiology with auditory
symptoms due to SCN1Amutation has not been pre-
viously reported, and our findings indicate EAF as a
novel phenotype within the SCN1A phenotypic
spectrum.
Mutations in SCN1A and DEPDC5 result in spe-
cific epilepsy syndromes, whereas CNTNAP2 is dis-
rupted in a broad range of neurologic conditions31–33
in which seizures play a part.26 Diallelic loss of normal
CNTNAP2 has been linked to complex phenotypes,
including cortical dysplasia and focal epilepsy,34,35 but
most of the disruptive events involving CNTNAP2
are heterozygous and show incomplete penetrance.
These include heterogeneous alterations ranging from
intronic/exonic deletions to splice-site mutations and
truncating and missense changes. Family A consists of
a nuclear pedigree with only 2 affected members,
father and daughter, who both have EAF. The exon
2-3 deletion we report, predicted to code for an
abnormal product (p.Gln33Argfs*7), lies within the
CNV hotspot spanning the CNTNAP2 exon 2-9
genomic region implicated in complex neuropsychi-
atric disorders (figure 2). Epilepsy or seizures are re-
ported in many of the patients with this deletion, but
they are not commonly the primary diagnosis and are
therefore not described in detail. Accurate epilepsy
phenotyping in these patients may reveal other EAF
cases associated with deletions of this gene. Neither
affected member of family A showed features of intel-
lectual disability, speech delay, or psychiatric distur-
bances. Notably, CASPR2, the protein product of
CNTNAP2, and LGI1 are closely associated with
the voltage-gated potassium channel (VGKC) com-
plex in the human brain (figure 2),36 and LGI1 has
Figure 2 The CNTNAP2 locus in disease and localization of its encoded product, CASPR2, at the synapse
(A) Schematic indicating the functional relationship linking LGI1 and CASPR2 proteins through the voltage-gated potassium
channel (VGKC). (B) Schematic indicating the previously reported microdeletions (horizontal bars) of CNTNAP2 in neuro-
psychiatric conditions (modified from Rodenas-Cuadrado, 2013). The deletion reported in this study, spanning CNTNAP2
exons 2-3, overlaps most of the CNTNAP2 deletions implicated in disorder before. It is represented in red with a halo
surrounding it. ADHD 5 attention-deficit/hyperactivity disorder; ASD 5 autism spectrum disorder.
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been found to be part of the CASPR2 interactome.37
This functional relationship highlights the possible
molecular link between CNTNAP2 disruption and
the EAF phenotype. Haploinsufficient Lgi1 in adult
rat brains has been demonstrated to cause changes in
the inactivation gating of presynaptic A-type chan-
nels, of which Kv1.1 is a major constituent.38 This
has been proposed to be the molecular mechanism
promoting epileptic activity in patients with defective
LGI1 protein. In addition, the predicted haploinsuf-
ficiency of CASPR2, another protein complexed with
Kv1.1, may alter channel kinetics. Recently, consis-
tent evidence has shown that mutations in the same
gene can increase the risk of a broad range of complex
neuropsychiatric disorders.39 This suggests the
involvement of genetic or environmental modifiers.
Notwithstanding the challenge in interpreting the
complexity of CNTNAP2 genotype-phenotype corre-
lations, the present data together with the accumu-
lated knowledge about CNTNAP2 mutations and
CASPR2 function strongly suggest that disrupted
CNTNAP2 contributes to EAF in family A. This per-
spective is fascinating because other pre- or postsyn-
aptic membrane-bound proteins (ADAM22,
ADAM23, and Kv1 channel genes) have been
explored before in search for mutations in EAF, but
no mutations were detected.8–10
Additional variants were identified in different
genes, either previously implicated in epilepsy
(CACNA1H, RELN) or not (EML6), but their actual
contribution to EAF cannot be assessed based on our
present observations.
Overall, defects in 3 novel genes were associated
with EAF. Of the pedigrees in which these mutations
were found, 1 with a CNTNAP2 deletion may have
ADEAF, as both affected individuals have the EAF
phenotype and the genetic inheritance model is auto-
somal dominant. The association of ADEAF with a
CNTNAP2 deletion shows biological convergence
and opens new perspectives on the contribution of
non-LGI1 VGKC-complex proteins to the EAF phe-
notype. The identification of mutations in DEPDC5
and SCN1A in families showing heterogeneous pheno-
typic patterns enlarges the phenotypic spectrum of the
epilepsies associated with these genes. Overall, our re-
sults suggest that EAF is an epilepsy phenotype origi-
nating from alterations in a heterogeneous group of
genes implicated in a broader range of epileptic syn-
dromes or neurologic diseases. This overlap, frequently
observed in other forms of epilepsy (e.g., autosomal
dominant nocturnal frontal lobe epilepsy),27,28 reflects
the complexity of the involved molecular mechanisms
and reveals the challenge of incorporating the under-
lying biology into the current classification of epilep-
sies. This study emphasizes the use of a comprehensive
WES strategy, tackling both mutations and CNVs, in
an effort to solve challenging diagnostic puzzles in
epilepsy.
AUTHOR CONTRIBUTIONS
Dr. Pippucci, Dr. Licchetta, S. Baldassari, and Dr. Bisulli conceptualized
and designed the study and drafted the manuscript. Dr. Menghi, Dr. Leta,
Dr. Stipa, Dr. Boero, Dr. d’Orsi, and Dr. Bisulli phenotyped the patients.
Dr. Pippucci, Dr. Licchetta, S. Baldassari, F. Palombo, Dr. D’Aurizio,
Dr. Magi, and Dr. Bisulli collected, analyzed, and interpreted the data.
Dr. Scheffer, Dr. Seri, and Dr. Tinuper critically revised the manuscript
for important intellectual content.
ACKNOWLEDGMENT
The authors are grateful to the families for participation in the study,
especially to the probands for their valuable assistance during in loco
assessment of the family. The authors acknowledge Mrs. Annalia Cesare
for secretarial help in keeping in contact with patients, Ms. Elena Zoni
for help in manuscript editing, and Dr. Lara Alvisi and the other EEG
technicians at our institute for recording the patients. The authors
acknowledge the genetic commission of the Italian League Against
Epilepsy for discussion of the pedigrees and valuable suggestions for
the study design.
STUDY FUNDING
Italian Ministry of Health Young Investigators project GR-2009-
1574072 to T.P. and F.B., Telethon Foundation Project GGP13200
to P.T. and T.P.
DISCLOSURE
Dr. Pippucci has worked for Azienda Ospedaliero-Universitaria Careggi and
has received research support from the Italian Ministry of Health and Tele-
thon Foundation. Dr. Licchetta reports no disclosures. S. Baldassari has
received research support from the Italian Ministry of Health and Telethon
Foundation. F. Palombo has received research support from the Italian
Ministry of Health and Telethon Foundation. Dr. Menghi, Dr. D’Aurizio,
Dr. Leta, Dr. Stipa, Dr. Boero, Dr. d’Orsi, and Dr. Magi report no dis-
closures. Dr. Scheffer has received funding for travel and/or speaker hono-
raria from Sanofi, UCB, and Transgenomics; has served on editorial boards
for Neurology, Epilepsy Currents, Annals of Neurology, Epileptic Disorders,
Progress in Epileptic Disorders series, and Virtual Neuro Centre; holds patents
for methods of treatment and diagnosis of epilepsy by detecting mutations
in the SCN1A gene, A Diagnostic Method for Epilepsy (also published as
Methods for the Diagnosis and Treatment of Epilepsy), Mutations in Ion
Channels, Diagnostic and Treatment Methods Relating to Autosomal
Dominant Nocturnal Frontal Lobe Epilepsy and pending patents for gene
and mutations thereof associated with seizure disorders, gene and mutations
thereof associated with seizure and movement disorders, and diagnostic and
therapeutic methods for EFMR; and has received research support from
NHMRC, NIH, The University of Melbourne, Austin Health Medical
Research Foundation, Melbourne Neurosciences Institute, Weizmann Insti-
tute, CURE SUDEP, and Perpetual Philanthropic Services. Dr. Seri reports
no disclosures. Dr. Tinuper has served on scientific advisory boards of UCB
Pharma and Cyberonics; has received funding for travel and/or speaker
honoraria from Cyberonics; and has served on the editorial board of Seiz-
ures. Dr. Bisulli has received research support from the Italian Ministry of
Health Young Investigators and Telethon. Go to Neurology.org/ng for full
disclosure forms.
Received March 18, 2015. Accepted in final form April 2, 2015.
REFERENCES
1. Ottman R, Risch N, Hauser WA, et al. Localization of a
gene for partial epilepsy to chromosome 10q. Nat Genet
1995;10:56–60.
2. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminol-
ogy and concepts for organization of seizures and epilep-
sies: report of the ILAE Commission on Classification and
Terminology, 2005–2009. Epilepsia 2010;51:676–685.
Neurology: Genetics 7
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
3. Morante-Redolat JM, Gorostidi-Pagola A, Piquer-
Sirerol S, et al. Mutations in the LGI1/Epitempin gene
on 10q24 cause autosomal dominant lateral temporal epi-
lepsy. Hum Mol Genet 2002;11:1119–1128.
4. Kalachikov S, Evgrafov O, Ross B, et al. Mutations in
LGI1 cause autosomal-dominant partial epilepsy with
auditory features. Nat Genet 2002;30:335–341.
5. Ottman R, Winawer MR, Kalachikov S, et al. LGI1 mu-
tations in autosomal dominant partial epilepsy with audi-
tory features. Neurology 2004;62:1120–1126.
6. Michelucci R, Pasini E, Malacrida S, et al. Low penetrance of
autosomal dominant lateral temporal epilepsy in Italian fam-
ilies without LGI1 mutations. Epilepsia 2013;54:1288–1297.
7. Bisulli F, Naldi I, Baldassari S, et al. Autosomal dominant
partial epilepsy with auditory features: a new locus on chro-
mosome 19q13.11-q13.31. Epilepsia 2014;55:841–848.
8. Chabrol E, Gourfinkel-An I, Scheffer IE, et al. Absence of
mutations in the LGI1 receptor ADAM22 gene in auto-
somal dominant lateral temporal epilepsy. Epilepsy Res
2007;76:41–48.
9. Diani E, Di Bonaventura C, Mecarelli O, et al. Autosomal
dominant lateral temporal epilepsy: absence of mutations
in ADAM22 and Kv1 channel genes encoding LGI1-
associated proteins. Epilepsy Res 2008;80:1–8.
10. Rigon L, Vettori A, Busolin G, et al. ADAM23, a gene
related to LGI1, is not linked to autosomal dominant lateral
temporal epilepsy. Epilepsy Res Treat 2011;2011:258365.
11. Magini P, Pippucci T, Tsai IC, et al. A mutation in PAK3
with a dual molecular effect deregulates the RAS/MAPK
pathway and drives an X-linked syndromic phenotype.
Hum Mol Genet 2014;23:3607–3617.
12. DePristo MA, Banks E, Poplin R, et al. A framework for
variation discovery and genotyping using next-generation
DNA sequencing data. Nat Genet 2011;43:491–498.
13. Magi A, Tattini L, Cifola I, et al. EXCAVATOR: detect-
ing copy number variants from whole-exome sequencing
data. Genome Biol 2013;14:R120.
14. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB.
Genic intolerance to functional variation and the interpreta-
tion of personal genomes. PLoS Genet 2013;9:e1003709.
15. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM,
Shendure J. A general framework for estimating the rela-
tive pathogenicity of human genetic variants. Nat Genet
2014;46:310–315.
16. Magini P, Bisulli F, Baldassari S, et al. LGI1 microdele-
tions are not a frequent cause of partial epilepsy with audi-
tory features (PEAF). Epilepsy Res 2014;108:972–977.
17. Bisulli F, Tinuper P, Avoni P, et al. Idiopathic partial epi-
lepsy with auditory features (IPEAF): a clinical and genetic
study of 53 sporadic cases. Brain 2004;127:1343–1352.
18. Lemke JR, Riesch E, Scheurenbrand T, et al. Targeted
next generation sequencing as a diagnostic tool in epileptic
disorders. Epilepsia 2012;53:1387–1398.
19. Bechi G, Rusconi R, Cestèle S, Striano P, Franceschetti S,
Mantegazza M. Rescuable folding defective Na(V)1.
1 (SCN1A) mutants in epilepsy: properties, occurrence,
and novel rescuing strategy with peptides targeted to the
endoplasmic reticulum. Neurobiol Dis 2015;6:100–114.
20. Heron SE, Khosravani H, Varela D, et al. Extended spectrum
of idiopathic generalized epilepsies associated with CACNA1H
functional variants. Ann Neurol 2007;62:560–568.
21. Folsom TD, Fatemi SH. The involvement of Reelin
in neurodevelopmental disorders. Neuropharmacology
2013;68:122–135.
22. Hong SE, Shugart YY, Huang DT, et al. Autosomal reces-
sive lissencephaly with cerebellar hypoplasia is associated
with human RELN mutations. Nat Genet 2000;26:93–96.
23. Dibbens LM, de Vries B, Donatello S, et al. Mutations in
DEPDC5 cause familial focal epilepsy with variable foci.
Nat Genet 2013;45:546–551.
24. Abou-Khalil B, Ge Q, Desai R, et al. Partial and general-
ized epilepsy with febrile seizures plus and a novel SCN1A
mutation. Neurology 2001;57:2265–2272.
25. Colosimo E, Gambardella A, Mantegazza M, et al. Electro-
clinical features of a family with simple febrile seizures and
temporal lobe epilepsy associated with SCN1A loss-of-
function mutation. Epilepsia 2007;48:1691–1696.
26. Rodenas-Cuadrado P, Ho J, Vernes SC. Shining a light on
CNTNAP2: complex functions to complex disorders. Eur
J Hum Genet 2014;22:171–178.
27. Picard F, Makrythanasis P, Navarro V, et al. DEPDC5 mu-
tations in families presenting as autosomal dominant noctur-
nal frontal lobe epilepsy. Neurology 2014;82:2101–2106.
28. Ishida S, Picard F, Rudolf G, et al. Mutations of DEPDC5
cause autosomal dominant focal epilepsies. Nat Genet
2013;45:552–555.
29. Escayg A, MacDonald BT, Meisler MH, et al. Mutations
of SCN1A, encoding neuronal sodium channel, in two
families with GEFS12. Nat Genet 2000;24:343–345.
30. Claes L, Del-Favero J, Ceulemans B, et al. De novo mu-
tations in the sodium-channel gene SCN1A cause severe
myoclonic epilepsy of infancy. Am J Hum Genet 2001;68:
1327–1332.
31. Lesca G, Rudolf G, Labalme A, et al. Epileptic encephalo-
pathies of the Landau-Kleffner and continuous spike and
waves during slow-wave sleep types: genomic dissection
makes the link with autism. Epilepsia 2012;53:1526–1538.
32. Gregor A, Albrecht B, Bader I, et al. Expanding the clinical
spectrum associated with defects in CNTNAP2 and
NRXN1. BMC Med Genet 2011;12:106.
33. Friedman JI, Vrijenhoek T, Markx S, et al. CNTNAP2
gene dosage variation is associated with schizophrenia and
epilepsy. Mol Psychiatry 2008;13:261–266.
34. Strauss KA, Puffenberger EG, Huentelman MJ, et al.
Recessive symptomatic focal epilepsy and mutant
contactin-associated protein-like 2. N Engl J Med 2006;
354:1370–1377.
35. Zweier C, de Jong EK, Zweier M, et al. CNTNAP2 and
NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-
like mental retardation and determine the level of a com-
mon synaptic protein in Drosophila. Am J Hum Genet
2009;85:655–666.
36. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1
potassium channel-complex proteins leucine-rich, glioma
inactivated 1 protein and contactin-associated protein-2 in
limbic encephalitis, Morvan’s syndrome and acquired neu-
romyotonia. Brain 2010;133:2734–2748.
37. Chen N, Koopmans F, Gordon A, et al. Interaction proteo-
mics of canonical Caspr2 (CNTNAP2) reveals the presence
of two Caspr2 isoforms with overlapping interactomes. Bio-
chim Biophys Acta Epub 2015 Feb 21.
38. Schulte U, Thumfart JO, Klöcker N, et al. The epilepsy-
linked Lgi1 protein assembles into presynaptic Kv1 chan-
nels and inhibits inactivation by Kvbeta1. Neuron 2006;
49:697–706.
39. Zhu X, Need AC, Petrovski S, Goldstein DB. One gene,
many neuropsychiatric disorders: lessons from Mendelian
diseases. Nat Neurosci 2014;17:773–781.
8 Neurology: Genetics
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
